Company intelligence / Profile preview

Taizhou Fudan-Zhangjiang Pharmaceutical

Taizhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Taizhou Fudan-Zhangjiang Pharmaceutical operates as a primary industrialization and manufacturing base for the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Group. It currently produces and markets photodynamic drugs such as Hemoporfin (FuMeiDa) and has advanced pipeline programs in late-stage clinical trials, including aminolevulinic acid for glioma visualization and various antibody-drug conjugates (ADCs) for oncology indications.

Therapeutic areas: OncologyDermatologyGastroenterology
Modalities: Small moleculeAntibody-drug conjugateLiposomePhotodynamic therapy
Industry: Biotech

Partnerships

Shanghai Pharmaceutical GroupNanjing Medical Co., Ltd.

Beyond the preview

Go deeper on Taizhou Fudan-Zhangjiang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taizhou Fudan-Zhangjiang Pharmaceutical.

Explore the full profile